Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2006-3-31
pubmed:abstractText
Linezolid is an oxazolidinone antibiotic that is increasingly used to treat drug-resistant, gram-positive pathogens. The mechanism of action is inhibition of bacterial protein synthesis. Optic and/or peripheral neuropathy and lactic acidosis are reported side effects, but the underlying pathophysiological mechanism has not been unravelled.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1537-6591
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1111-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16575728-Acetamides, pubmed-meshheading:16575728-Animals, pubmed-meshheading:16575728-Anti-Infective Agents, pubmed-meshheading:16575728-DNA, Mitochondrial, pubmed-meshheading:16575728-Drug Therapy, Combination, pubmed-meshheading:16575728-Female, pubmed-meshheading:16575728-Humans, pubmed-meshheading:16575728-Kidney, pubmed-meshheading:16575728-Male, pubmed-meshheading:16575728-Middle Aged, pubmed-meshheading:16575728-Mitochondria, pubmed-meshheading:16575728-Mitochondria, Liver, pubmed-meshheading:16575728-Mitochondria, Muscle, pubmed-meshheading:16575728-Oxazolidinones, pubmed-meshheading:16575728-Protein Synthesis Inhibitors, pubmed-meshheading:16575728-Rats, pubmed-meshheading:16575728-Rats, Sprague-Dawley, pubmed-meshheading:16575728-Rifampin, pubmed-meshheading:16575728-Staphylococcal Infections
pubmed:year
2006
pubmed:articleTitle
Linezolid-induced inhibition of mitochondrial protein synthesis.
pubmed:affiliation
Department of Internal Medicine, AZ Sint-Jan AV, Bruges, Belgium. an.devriese@azbrugge.be
pubmed:publicationType
Journal Article, Case Reports, Research Support, Non-U.S. Gov't